close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

43.93 +1.70 (+4.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

News headline image
Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022
From Moderna, Inc.
Via Business Wire
News headline image
Moderna to Report Second Quarter Financial Results on Thursday, August 5, 2021
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Recipharm Site in France Manufacturing COVID-19 Vaccine Moderna Following Approval by European Medicines Agency
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Emergency Use Authorization for its COVID-19 Vaccine Granted by Government of India
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India
From Moderna, Inc.
Via Business Wire
News headline image
Kate Cronin to Join Moderna as Chief Brand Officer on July 12
From Moderna, Inc.
Via Business Wire
News headline image
European Commission Purchases Additional 150 Million Doses of Moderna’s COVID-19 Vaccine for Delivery in 2022
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Reaffirms Commitment to Job Creation in Massachusetts
From Moderna, Inc.
Via Business Wire
News headline image
U.S. Government Purchases Additional 200 Million Doses of Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna and Magenta Partner to Distribute Moderna’s COVID-19 Vaccine and Updated Variant Booster Candidates in United Arab Emirates
From Moderna, Inc.
Via Business Wire
News headline image
Dr. Paul Burton to Join Moderna as Chief Medical Officer
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Submits Authorization Application for its COVID-19 Vaccine in Adolescents in Switzerland
From Moderna, Inc.
Via Business Wire
News headline image
Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Files for Emergency Use Authorization for its COVID-19 Vaccine in Adolescents in the United States
From Moderna, Inc.
Via Business Wire
News headline image
Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Files for Authorization with Health Canada for its COVID-19 Vaccine in Adolescents
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Agreement to Supply the Republic of Botswana with its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Why The Relaxation In Lockdowns Is Expected To Drive The Demand For COVID-19 Diagnostics Market
Via FinancialNewsMedia
News headline image
UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna to Present at Upcoming Investor Conferences in June 2021
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June
From Moderna, Inc.
Via Business Wire
News headline image
Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline
From Moderna, Inc.
Via Business Wire
News headline image
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today